五十嵐 中

論文

• Return on investment of national specific health guidance in Japan: an observational study using "Wellness-Star⋆" health insurance claims database.

  Takuma Ueda, Akihiro Kakinuma, Masaru Kinugawa, Shugo Yajima, Yuri Miyamori, Takumi Kakoi, Sayuri Yamamoto, Tianyi Zhang, Tomomi Takeshima, Ayano Chida …

  Journal of medical economics 29(1) 688-697 2026年12月
• Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off study.

  Regina Rendas-Baum, Jakob Bjorner, Victor Preckler, Taizo Matsuki, Yufan Ho, Daniel Molnar, Shinichi Noto, Ataru Igarashi

  Expert review of pharmacoeconomics & outcomes research 1-9 2026年5月15日
• The social value of lecanemab for patients with early Alzheimer's disease in Japan.

  Ataru Igarashi, Mie Azuma-Kasai, Mayaka Tani, Takuro Utsumi, Hidetoshi Shibahara, Sachie Inoue, Simon Rothwell, Gaku Kamanaka, Yukinori Sakata, Hironobu Hiyoshi …

  Journal of Alzheimer's disease : JAD 13872877261447312-13872877261447312 2026年5月10日
• Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.

  Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Iori Motohashi, Hiroshi Kamura …

  Vaccine 80 128544-128544 2026年4月30日
• Cost-Effectiveness Analysis of Fecal Immunochemical Test- and Colonoscopy-based Colorectal Cancer Screening across Varying Uptake Rates.

  Masau Sekiguchi, Ataru Igarashi, Minoru Esaki, Yutaka Saito, Nozomu Kobayashi, Takahisa Matsuda

  DEN open 6(1) e70236 2026年4月
• Author's reply to 'Trends in Usage and Drug Costs of Immune-Checkpoint Inhibitors in Japan'.

  Akina Takami, Koki Yamashita, Ataru Igarashi

  Japanese journal of clinical oncology 2026年3月30日
• Socioeconomic burden of adult attention deficit/hyperactivity disorder in Japan: a nationwide cross-sectional observational study.

  Ataru Igarashi, Nobuhiro Nishigaki, Yasushi Kawakita, Noa Tsujii

  BMC psychiatry 26(1) 2026年3月28日
• Cost-effectiveness analysis of intensity modulated radiation therapy versus robot-assisted radical prostatectomy for patients with low-risk prostate cancer in Japan.

  Ataru Igarashi, Keiichi Jingu, Kaoru Ito, Ritsuko Koba, David W Lee

  Journal of radiation research 67(2) 266-275 2026年3月25日
• Health economic analysis of seizure-related emergency visits of pediatric patients with drug-resistant epilepsy in Japan.

  Ayataka Fujimoto, Takuya Kumagai, Kazuaki Yamamoto, Katsuhiko Iwasaki, Kinya Kokubo, Ataru Igarashi

  Epilepsy & behavior reports 33 100840-100840 2026年3月
• Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan.

  Akina Takami, Gen Terashima, Takumi Tajima, Koki Yamashita, Ataru Igarashi

  Drugs - real world outcomes 13(1) 101-110 2026年3月
• Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.

  Kei Koizumi, Ataru Igarashi, Mark Gouldson, Sandeep Bilthare, Sebastien Eymere, Gebra Cuyún-Carter, Steve Millen, Mariko Nomoto, Yoshie Onishi, Aki Kudo …

  Breast cancer (Tokyo, Japan) 33(2) 499-509 2026年3月
• Incidence of RSV- and Influenza-Associated Hospitalizations With Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022-2024: APSG-J2 Study.

  Haruka Maeda, Shingo Masuda, Bhim Gopal Dhoubhadel, Yuka Fujita, Yuji Akiba, Yutaka Nishigaki, Kei Nakashima, Hiroyuki Ito, Masayuki Nogi, Yoshihito Otsuka …

  Influenza and other respiratory viruses 20(3) e70238 2026年3月
• Designing an Indicator‐Driven, Value‐Based Architecture for Pneumonia Prevention in Japan: A Formative Policy Viewpoint on Adult Vaccination and Oral Care

  Kazumi Kubota, Ataru Igarashi, Satoko Fujihara, Kenichi Imai

  JMIR Formative Research 10 e86912-e86912 2026年2月27日
• Updated Conversion Table for the Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE".

  Akina Takami, Ataru Igarashi

  Journal of market access & health policy 14(1) 2026年2月25日
• Trends in usage and drug costs of immune checkpoint inhibitors in Japan.

  Akina Takami, Koki Yamashita, Ataru Igarashi

  Japanese journal of clinical oncology 56(2) 155-167 2026年2月13日
• Economic consequences when enteral tube feeding intolerance causes unplanned discontinuation in hospitalized older patients with gastroesophageal reflux disease.

  Yukikazu Kamada, Kanako Kawano, Akina Iguchi, Noriko Tominaga, Chisato Okamoto, Masatoshi Inoue, Ataru Igarashi, Masafumi Kitakaze

  Clinical nutrition ESPEN 71 102892-102892 2026年2月
• Longitudinal Changes in Utilities and HRQoL During Interferon‐Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‐Utility Analysis

  Maki Hirao, Ataru Igarashi, Hiroshi Yatsuhashi, Toshihiko Sato, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Tomoyuki Takura, Takeshi Yoda, Manabu Akazawa …

  2026年1月29日 査読有り
• Incidence of COVID-19-Associated Hospitalization by Vaccination Status in Children and Adolescents During Omicron-Dominant Period in Japan: The VENUS Study.

  Haruka Maeda, Michiko Toizumi, Ataru Igarashi, Megumi Maeda, Futoshi Oda, Haruhisa Fukuda

  Children (Basel, Switzerland) 13(2) 2026年1月28日
• Cost-utility analysis of treatment strategies for chronic constipation in Japan.

  Mariko Hojo, Ataru Igarashi, Ayako Shoji, Akihito Nagahara

  Journal of gastroenterology 61(1) 59-67 2026年1月
• Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan.

  Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi

  Drug, healthcare and patient safety 18 583501-583501 2026年